Bryan Garnier - Cellectis ADS (CLLS) Reports Q1 2023 results, stops UCARTCS1 trial

Report

Bryan Garnier

Ingird Gafanhão

Reports Q1 2023 results, stops UCARTCS1 trial

Cellectis reported Q1 2023 results, with revenues of USD 3.6m (USD 3.8m), reflecting the recognition of USD 1.5m in milestones related to Cellectis’ agreement with Cytovia, R&D expenses of USD 21.1m (USD 26.6m), and SG&A expenses of USD 5.0 m (USD 6.1m). The company reported a decreased net

05/05/2023 1 EN

Underlying

Cellectis ADS

See profile

US15117K1034 NASDAQ Stock Market France

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Ingird Gafanhão

Other Reports on these Companies

Bryan Garnier

End of coverage

From 5th February, we will no longer include in our research universe:Adaptimmune, ALK, argenx, Autolus, Cellectis, Galapagos, Hansa Biopharma, Heidelberg Pharma, Immatics, Immunocore, Ipsen, Moonlake Immunotherapeutics, Pharvaris, UCB, Vivoryon Therapeutics, Zealand Pharma, Nicox, GenSight Biologi

February 5, 2024 February 5, 2024 1 EN

Bryan Garnier

Coverage update

Given team and strategy changes, Alex Cogut is now assuming coverage of Achilles Therapeutics, Adaptimmune Therapeutics, Autolus, Calliditas, Cellectis, Galapagos, GenSight, Hansa Biopharma, Heidelberg Pharma, Immunocore, Innate Pharma, Sesorion and ValerioWe drop coverage of Celyad Oncology BioNte

September 28, 2023 September 28, 2023 1 EN

Bryan Garnier

Conference updates: takeaways from ASCO and ISCT

We wrap up the past conference-filled weeks with a summary of the main takeaways from our coverage. From the International Society for Cell & Gene Therapy (ISCT) meeting, we point out i) Cellectis preclinical updates, and ii) a KOL dinner we hosted with Dr Bruce Levine discussing how to improve

June 9, 2023 June 9, 2023 1 EN

Discontinuing Coverage Ahead of Stifel Integration

On June 2, 2025, Stifel Financial Corporation acquired Bryan, Garnier & Co Limited and Bryan Garnier Securities, which have been rebranded to Stifel Europe Limited and Stifel Europe Securities, respectively. Today, August 22, 2025, both entities are being integrated into the Stifel research pla

August 22, 2025 August 22, 2025 1 EN

Stifel Europe Limited Research

Stifel Europe Limited Research

Discontinuing Coverage

We are discontinuing coverage of the companies listed in the chart below. Our past recommendations on these names should no longer be relied upon.

August 21, 2025 August 21, 2025 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Alfen: H1 2025 results, mid-term outlook lowered

Alfen published H1 2025 figures yesterday. Revenue came in at EUR211.5m (-13.9% YoY vs. EUR245.7m in H1 2024) mainly with challenging dynamics in EV charging and Energy Storage, while benefiting from favourable base effects in Smart Grids, which was impacted by moistening issues in Q2 2024. This wa

August 21, 2025 August 21, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Reports Q1 2023 results, stops UCARTCS1 trial

End of coverage

Coverage update

Conference updates: takeaways from ASCO and ISCT

Discontinuing Coverage Ahead of Stifel Integration

Discontinuing Coverage

Alfen: H1 2025 results, mid-term outlook lowered

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe